NCT07847671Not yet recruitingPhase 2
Fecal Microbiota Transplantation Combined With QL1706 Plus Bevacizumab for Advanced HCC
Fecal Microbiota Transplantation （FMT） Combined With QL1706 Plus Bevacizumab as First-line Treatment for Advanced HCC
Source: ClinicalTrials.gov · Last updated 8 Oct 2026
Brief summary (registry, in English)
This is a prospective, single-center, single-arm Phase II pilot study designed to evaluate the efficacy and safety of FMT in combination with QL1706 and Bevacizumab as first-line treatment for advanced Hepatocellular carcinoma.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- First submitted
- 16 Sept 2026
- Start date
- Oct 2026
- Primary completion date
- Oct 2029
- Lead sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Diseases
- Liver and biliary tract cancer
- NCT number
- NCT07847671
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 20
- From Oct 2026 to the primary completion date, Oct 2029
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior treatment with an immune checkpoint inhibitor, or prior systemic therapy for advanced HCC.
- Active or prior autoimmune disease, immunodeficiency requiring systemic immunosuppressive therapy.
- Any contraindication to fecal microbiota transplantation.
Other illness
- Clinically significant bleeding risk, coagulopathy, or untreated high-risk esophagogastric varices.
- Uncontrolled intercurrent illness, including active infection, clinically significant cardiovascular disease, central nervous system metastases.
Other
- Histologic subtypes other than hepatocellular carcinoma, including fibrolamellar HCC, sarcomatoid HCC, and mixed hepatocellular cholangiocarcinoma.
- Pregnancy or breastfeeding.
Who the study is looking for
- Age \>18 years.
- Confirmed imaging or histological diagnosis of unresectable HCC.
- Treatment-naïve unresectable or metastatic HCC.
- BCLC Stage C.
- Child-Pugh A.
- ECOG PS 0-1.
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Tianjin Medical University Cancer Institute and Hospital Coordinator of this site? Confirm its status | Tianjin | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.